Tiet Quyen Q, Leyva Yani E, Moos Rudolf H, Smith Brandy
VA Palo Alto Health Care System, Palo Alto, CA, United States; Stanford University School of Medicine, Stanford, CA, United States; California School of Professional Psychology at Alliant International University, San Francisco, CA, United States.
VA Palo Alto Health Care System, Palo Alto, CA, United States.
Addict Behav. 2017 Nov;74:112-117. doi: 10.1016/j.addbeh.2017.06.008. Epub 2017 Jun 8.
Drug use is prevalent and costly to society, but individuals with drug use disorders (DUDs) are under-diagnosed and under-treated, particularly in primary care (PC) settings. Drug screening instruments have been developed to identify patients with DUDs and facilitate treatment. The Drug Abuse Screening Test (DAST) is one of the most well-known drug screening instruments. However, similar to many such instruments, it is too long for routine use in busy PC settings. This study developed and validated a briefer and more practical DAST for busy PC settings.
We recruited 1300 PC patients in two Department of Veterans Affairs (VA) clinics. Participants responded to a structured diagnostic interview. We randomly selected half of the sample to develop and the other half to validate the new instrument. We employed signal detection techniques to select the best DAST items to identify DUDs (based on the MINI) and negative consequences of drug use (measured by the Inventory of Drug Use Consequences). Performance indicators were calculated.
The two-item DAST (DAST-2) was 97% sensitive and 91% specific for DUDs in the development sample and 95% sensitive and 89% specific in the validation sample. It was highly sensitive and specific for DUD and negative consequences of drug use in subgroups of patients, including gender, age, race/ethnicity, marital status, educational level, and posttraumatic stress disorder status.
The DAST-2 is an appropriate drug screening instrument for routine use in PC settings in the VA and may be applicable in broader range of PC clinics.
药物使用在社会中普遍存在且成本高昂,但患有药物使用障碍(DUDs)的个体诊断不足且治疗不足,尤其是在初级保健(PC)机构中。已开发出药物筛查工具来识别患有DUDs的患者并促进治疗。药物滥用筛查测试(DAST)是最著名的药物筛查工具之一。然而,与许多此类工具一样,它过长,不适合在繁忙的PC机构中常规使用。本研究针对繁忙的PC机构开发并验证了一种更简短、更实用的DAST。
我们在两个退伍军人事务部(VA)诊所招募了1300名PC患者。参与者接受了结构化诊断访谈。我们随机选择一半样本进行新工具的开发,另一半进行验证。我们采用信号检测技术选择最佳的DAST项目以识别DUDs(基于MINI)和药物使用的负面后果(通过药物使用后果清单测量)。计算了性能指标。
两项版DAST(DAST - 2)在开发样本中对DUDs的敏感性为97%,特异性为91%,在验证样本中敏感性为95%,特异性为89%。在包括性别、年龄、种族/族裔、婚姻状况、教育水平和创伤后应激障碍状态等患者亚组中,它对DUDs和药物使用的负面后果具有高度敏感性和特异性。
DAST - 2是一种适用于VA中PC机构常规使用的药物筛查工具,可能适用于更广泛的PC诊所。